Werner's syndrome as a hereditary risk factor for exocrine pancreatic cancer: Potential role of WRN in pancreatic tumorigenesis and patient-tailored therapy

Cancer Biology and Therapy

Volumn 10, Issue 5, 2010, Pages 430-437

  Chun, Stephen G ^a,b   Yee, Nelson S ^c,d  

^a UNIVERSITY OF HAWAII   (United States)

^b UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Adult onset progeria; DNA repair syndrome; Exonuclease; Pancreatic adenocarcinoma; RecQ helicase; Tumor suppressor gene; Werner's syndrome; WRN

Indexed keywords

APC PROTEIN; ATM PROTEIN; AZACITIDINE; BRCA2 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EXONUCLEASE; HISTONE DEACETYLASE INHIBITOR; PROTEIN KINASE LKB1; PROTEIN MSH2; PROTEIN P53; RECQ HELICASE; SMALL INTERFERING RNA; STRATUM CORNEUM CHYMOTRYPTIC ENZYME; WERNER SYNDROME PROTEIN; EXODEOXYRIBONUCLEASE; WRN PROTEIN, HUMAN;

ADENOMATOUS POLYP; ADULT; ARTICLE; ATAXIA TELANGIECTASIA; CANCER CELL CULTURE; CANCER MODEL; CANCER SUSCEPTIBILITY; CARCINOGENICITY; CASE REPORT; DISEASE ASSOCIATION; DNA DAMAGE; DNA HELIX; DNA REPLICATION; EXPERIMENTAL MODEL; FAILURE TO THRIVE; FEMALE; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LOSS OF FUNCTION MUTATION; MALE; MALIGNANT NEOPLASTIC DISEASE; OBSTRUCTIVE JAUNDICE; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PANCREAS CARCINOMA; PANCREAS TUMOR; PANCREATICODUODENECTOMY; PANCREATITIS; PEUTZ JEGHERS SYNDROME; RISK FACTOR; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; WERNER SYNDROME; ADENOCARCINOMA; AGING; CELL TRANSFORMATION; CHROMOSOME 8; DISORDERS OF DNA SYNTHESIS AND REPAIR; GENE SILENCING; GENETIC EPIGENESIS; GENETIC PREDISPOSITION; GENETICS; METABOLISM; ONCOGENE RAS; PATHOLOGY; TUMOR CELL LINE;

ADENOCARCINOMA; ADULT; AGING; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOMES, HUMAN, PAIR 8; DNA REPAIR-DEFICIENCY DISORDERS; EPIGENESIS, GENETIC; EXODEOXYRIBONUCLEASES; FEMALE; GENE SILENCING; GENES, RAS; GENES, TUMOR SUPPRESSOR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; PANCREATIC NEOPLASMS; RECQ HELICASES; RISK FACTORS; WERNER SYNDROME;

EID: 77957163485     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.10.5.12763     Document Type: Article

References (84)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics 2009. CA Cancer J Clin 2009; 59:15-20.
2. Strimpakos A, Saif MW, Syrigos KN. Pancreatic cancer: from molecular pathogenesis to targeted therapy. Cancer Met Rev 2008; 27:495-522.
3. Yee NS. Zebrafish as a biological system for identifying and evaluating therapeutic targets and compounds. In Drug discovery in pancreatic cancer 2010; 95-112. (edited by Han H, Grippo PJ) New York: Springer.
4. Koorstra JBM, Hustinx SR, Offerhaus GJA, Maitra A. Pancreatic carcinogenesis. Pancreatology 2008; 8:110-25.
5. Hruban RH, Wilentz RE, Kern SE. Genetic progression in the pancreatic ducts. Am J Pathol 2000; 156:1821-5.
6. van Heek NT, Meeker AK, Kern SE, Yeo CJ, Lillemoe KD, Cameron JL, et al. Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol 2002; 161:1541-7.
7. Kaino M. Alterations in the tumor suppressor genes p53, RB, p16/MTS1 and p15/MTS2 in human pancreatic cancer and hepatoma cell lines. J Gastroenterol 1997; 32:40-6. (Pubitemid 27075880)
8. Ghaneh P, Costello E, Neoptolemos JP. Biology and management of pancreatic cancer. Gut 2007; 56:1134-52.
9. Chun SG, Zhou W, Yee NS. Combined targeting of histone deacetylases and hedgehog signaling enhances cytotoxicity in pancreatic cancer. Cancer Biol Ther 2009; 8:1328-39.
10. Yee NS, Furth EE, Pack M. Clinicopathologic and molecular features of pancreatic adenocarcinoma associated with Peutz-Jeghers syndrome. Cancer Biol Ther 2003; 2:38-47.
11. Lochan R, Daly AK, Reeves HL, Charnley RM. Genetic susceptibility in pancreatic ductal adenocarcinoma. Br J Surg 2008; 95:22-32. (Pubitemid 351184912)
12. Gray MD, Shen JC, Kamath-Loeb AS, Blank A, Sopher BL, Martin GM, et al. The Werner syndrome protein is a DNA helicase. Nat Genet 1997; 17:100-3. (Pubitemid 27377541)
13. Suzuki N, Shimamoto A, Imamura O, Kuromitsu J, Kitao S, Goto M, Furuichi Y. DNA helicase activity in Werner's syndrome gene product synthesized in a baculovirus system. Nucleic Acids Res 1997; 25:2973-8. (Pubitemid 27331388)
14. Huang S, Li B, Gray MD, Oshima J, Mian IS, Campisi J. The premature ageing syndrome protein, WRN, is a 3′→5′ exonuclease. Nat Genet 1998; 20:114-6.
15. Salk D. Werner's syndrome: a review of recent research with an analysis of connective tissue metabolism, growth control of cultured cells and chromosomal aberrations. Hum Genet 1982; 62:1-5. (Pubitemid 13201988)
16. Yu CE, Oshima J, Fu YH, Wijsman EM, Hisama F, Alisch R, et al. Positional cloning of the Werner's syndrome gene. Science 1996; 272:258-62.
17. Goto M, Miller RW, Ishikawa Y, Sugano H. Excess of rare cancers in Werner syndrome (adult progeria). Cancer Epidemiol Biomarkers Prev 1996; 5:239-46.
18. Yu CE, Oshima J, Wijsman EM, Nakura J, Miki T, Piussan C, et al. Mutations in the consensus helicase domains of the Werner syndrome gene. Werner's Syndrome Collaborative Group. Am J Hum Genet 1997; 60:330-41.
19. Matsumoto T, Imamura O, Yamabe Y, Kuromitsu J, Tokutake Y, Shimamoto A. Mutation and haplotype analyses of the Werner's syndrome gene based on its genomic structure: genetic epidemiology in the Japanese population. Hum Genet 1997; 100:123-30.
20. Hickson ID. RecQ helicases: caretakers of the genome. Nat Rev Cancer 2003; 3:169-78.
21. Thweatt R, Goldstein S. Werner syndrome and biological ageing: a molecular genetic hypothesis. Bioessays 1993; 15:421-6.
22. Ozgenc A, Loeb LA. Werner Syndrome, Aging and Cancer. Genome Dyn 2006; 1:206-17.
23. Toyoshima H. A case of Werner's syndrome with pancreatic carcinoma. Nishinihon J Dermatol 1986; 49:157.
24. Shimaoka Y, Hatamochi A, Hamasaki Y, Yamazaki S, Hiraishi H, Hattori Y, et al. Case of Werner's syndrome with pancreatic carcinoma. J Dermatol 2007; 34:674-6.
25. Chun SG, Yee NS, Holland JM, Shohet RV, Palalay MP, Bryant-Greenwood PK. Pancreatic adenocarcinoma associated with Werner's syndrome (adult-onset progeria). Gastrointest Cancer Res 2010; In press.
26. Satoh M, Imai M, Sugimoto M, Goto M, Furuichi Y. Prevalence of Werner's syndrome heterozygotes in Japan. Lancet 1999; 353:1766. (Pubitemid 29240383)
27. Gold EB, Goldin SB. Epidemiology of and risk factors for pancreatic cancer. Surg Oncol Clin N Am 1998; 7:67-91. (Pubitemid 28108793)
28. Lüttges J, Stigge C, Pacena M, Klöppel G. Rare ductal adenocarcinoma of the pancreas in patients younger than age 40 years. Cancer 2004; 100:173-82.
29. Sidorova JM, Li N, Folch A, Monnat RJ Jr. The RecQ helicase WRN is required for normal replication fork progression after DNA damage or replication fork arrest. Cell Cycle 2008; 7:796-807. (Pubitemid 351520044)
30. Shen JC, Lao Y, Kamath-Loeb A, Wold MS, Loeb LA. The N-terminal domain of the large subunit of human replication protein A binds to Werner syndrome protein and stimulates helicase activity. Mech Ageing Dev 2003; 124:921-30. (Pubitemid 37130142)
31. Lee SJ, Yook JS, Han SM, Koo HS. A Werner syndrome protein homolog affects C. elegans development, growth rate, life span and sensitivity to DNA damage by acting at a DNA damage checkpoint. Development 2004; 131:2565-75.
32. Blander G, Kipnis J, Leal JF, Yu CE, Schellenberg GD, Oren M. Physical and functional interaction between p53 and the Werner's syndrome protein. J Biol Chem 1999; 274:29463-9. (Pubitemid 29477118)
33. Martin GM, Sprague CA, Epstein CJ. Replicative life-span of cultivated human cells. Effects of donor's age, tissue and genotype. Lab Invest 1970; 23:86-92.
34. Chang S, Multani AS, Cabrera NG, Naylor ML, Laud P, Lombard D, et al. Essential role of limiting telomeres in the pathogenesis of Werner syndrome. Nat Genet 2004; 36:877-82.
35. Opresko PL. Telomere ResQue and preservation-roles for the Werner syndrome protein and other RecQ helicases. Mech Ageing Dev 2008; 129:79-90.
36. Opresko PL, Calvo JP, von Kobbe C. Role for the Werner syndrome protein in the promotion of tumor cell growth. Mech Ageing Dev 2007; 128:423-36. (Pubitemid 47223376)
37. Agrelo R, Cheng WH, Setien F, Ropero S, Espada J, Fraga MF, et al. Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer. Proc Natl Acad Sci USA 2006; 103:8822-7.
38. Chughtai SA, Crundwell MC, Cruickshank NR, Affie E, Armstrong S, Knowles MA, et al. Two novel regions of interstitial deletion on chromosome 8p in colorectal cancer. Oncogene 1999; 18:657-65.
39. Armes JE, Hammet F, de Silva M, Ciciulla J, Ramus SJ, Soo WK, et al. Candidate tumor-suppressor genes on chromosome arm 8p in early-onset and high-grade breast cancers. Oncogene 2004; 23:5697-702.
40. Turaga RVN, Paquet ER, Sild M, Vignard J, Garand C, Johnson FB, et al. The Werner syndrome protein affects the expression of genes involved in adipogenesis and inflammation in addition to cell cycle and DNA damage responses. Cell Cycle 2009; 8:2080-92.
41. Liu Y, El-Naggar S, Clem B, Chesney J, Dean DC. The Rb/E2F pathway and Ras activation regulate RecQ helicase gene expression. Biochem J 2008; 412:299-306. (Pubitemid 351758235)
42. Zhou B, Ikejima T, Watanabe T, Iwakoshi K, Idei Y, Tanuma S, Uchiumi F. The effect of 2-deoxy-D-glucose on Werner syndrome RecQ helicase gene. FEBS Lett 2009; 583:1331-6.
43. Von Kobbe C, May A, Grandori C, Bohr VA. Werner syndrome cells escape hydrogen peroxide-induced cell proliferation arrest. FASEB J 2004; 18:1970-2. (Pubitemid 39602301)
44. Coleman MC, Asbury CR, Daniels D, Du J, Aykin- Burns N, Smith BJ, et al. 2-deoxy-D-glucose causes cytotoxicity, oxidative stress and radiosensitization in pancreatic cancer. Free Radic Biol Med 2008; 44:322-31.
45. Gosselin K, Martien S, Pourtier A, Vercamer C, Ostoich P, Morat L, et al. Senescence-associated oxidative DNA damage promotes the generation of neoplastic cells. Cancer Res 2009; 69:7917-25.
46. Chen L, Oshima J. Werner Syndrome. J Biomed Biotechnol 2002; 2:46-54.
47. Alter BP. Cancer in Fanconi anemia 1927-2001. Cancer 2003; 97:425-40.
48. Lindor NM, Petersen GM, Hadley DW, Kinney AY, Miesfeldt S, Lu KH, et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 2006; 296:1507-17. (Pubitemid 44465515)
49. Hollander MC, Philburn RT, Patterson AD, Velasco- Miguel S, Friedberg EC, et al. Deletion of XPC leads to lung tumors in mice and is associated with early events in human lung carcinogenesis. Proc Natl Acad Sci USA 2005; 102:13200-5.
50. Rapin I, Lindenbaum Y, Dickson DW, Kraemer KH, Robbins JH. Cockayne syndrome and xeroderma pigmentosum. Neurology 2000; 55:1442-9.
51. De Sanctis C, Cacchione A. L' Idiozia xerodermica. Riv Sperm Freniatr 1932; 56:269-92.
52. van der Horst GT, van Steeg H, Berg RJ, van Gool AJ, de Wit J, Weeda G, et al. Defective transcription-coupled repair in Cockayne syndrome B mice is associated with skin cancer predisposition. Cell 1997; 89:425-35.
53. Hoeijmakers JH. DNA damage, aging and cancer. N Engl J Med 2009; 361:1475-85.
54. German J. Bloom's syndrome. XX. The first 100 cancers. Cancer Genet Cytogenet 1997; 93:100-6.
55. Kellermayer R. The versatile RECQL4. Genet Med 2006; 8:213-6.
56. Kudlow BA, Kennedy BK, Monnat RJ Jr. Werner and Hutchinson-Gilford progeria syndromes: mechanistic basis of human progeroid diseases. Nat Rev Mol Cell Biol 2007; 8:394-404.
57. Stefanini M, Botta E, Lanzafame M, Orioli D. Trichothiodystrophy: from basic mechanisms to clinical implications. DNA Repair (Amst) 2010; 9:2-10.
58. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability - an evolving hallmark of cancer. Nat Rev Mol Cell Biol 2010; 11:220-8.
59. Ryu B, Song J, Sohn T, Hruban RH, Kern SE. Frequent germline deletion polymorphism of chromosomal region 8p12-p21 identified as a recurrent homozygous deletion in human tumors. Genomics 2001; 72:108-12. (Pubitemid 32225186)
60. Fuchs CS, Colditz GA, Stampfer MJ, Giovannucci EL, Hunter DJ, Rimm EB, et al. A prospective study of cigarette smoking and the risk of pancreatic cancer. Arch Intern Med 1996; 156:2255-60.
61. Schenk M, Schwartz AG, O'Neal E, Kinnard M, Greenson JK, Fryzek JP, et al. Familial risk of pancreatic cancer. J Natl Cancer Inst 2001; 93:640-4.
62. Nyunoya T, Monick MM, Klingelhutz AL, Glaser H, Cagley JR, Brown CO, et al. Cigarette smoke induces cellular senescence via Werner's syndrome protein downregulation. Am J Respir Crit Care Med 2009; 179:279-87.
63. Hegi ME, Sciuscio D, Murat A, Levivier M, Stupp R. Epigenetic deregulation of DNA repair and its potential for therapy. Clin Cancer Res 2009; 15:5026-31.
64. Dong YP, Seki M, Yoshimura A, Inoue E, Furukawa S, Tada S, Enomoto T. WRN functions in a RAD18-dependent damage avoidance pathway. Biol Pharm Bull 2007; 30:1080-3. (Pubitemid 46883869)
65. Li K, Wang R, Lozada E, Fan W, Orren DK, Luo J. Acetylation of WRN protein regulates its stability by inhibiting ubiquitination. PLoS One 2010; 5:10341.
66. Giardiello FM, Brensinger JD, Tersmette AC, Goodman SN, Petersen GM, Booker SV, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000; 119:1447-53.
67. Lowenfels AB, Maisonneuve P, DiMagno EP, Elitsur Y, Gates LK Jr, Perrault J, Whitcomb DC. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst 1997; 89:442-6.
68. Lowenfels AB, Maisonneuve P, Whitcomb DC, Lerch MM, DiMagno EP. Cigarette smoking as a risk factor for pancreatic cancer in patients with hereditary pancreatitis. JAMA 2001; 286:169-70. (Pubitemid 32640846)
69. Vasen HF, Gruis NA, Frants RR, van Der Velden PA, Hille ET, Bergman W. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer 2000; 87:809-11. (Pubitemid 30660559)
70. Landi S. Genetic predisposition and environmental risk factors to pancreatic cancer: A review of the literature. Mutat Res 2009; 681:299-307.
71. Lefrou L, Godart B, de Muret A, Scotto B, Dorval E. Germline tp53 neomutation in a patient with Li-Fraumeni syndrome and pancreatic adenocarcinoma. Gastroenterol Clin Biol 2006; 30:484-6.
72. Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Boland CR. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis and medicolegal ramifications. Clin Genet 2009; 76:1-18.
73. Swift M, Sholman L, Perry M, Chase C. Malignant neoplasms in the families of patients with ataxia-telangiectasia. Cancer Res 1976; 36:209-15.
74. Lynch HT, Deters CA, Lynch JF, Brand RE. Familial pancreatic carcinoma in Jews. Fam Cancer 2004; 3:233-40.
75. Goggins M, Schutte M, Lu J, Moskaluk CA, Weinstein CL, Petersen GM, et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996; 56:5360-4.
76. Lal G, Liu G, Schmocker B, Kaurah P, Ozcelik H, Narod SA, et al. Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1 and BRCA2 mutations. Cancer Res 2000; 60:409-16.
77. Murphy KM, Brune KA, Griffin C, Sollenberger JE, Petersen GM, Bansal R, et al. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res 2002; 62:3789-93.
78. Hahn SA, Greenhalf B, Ellis I, Sina-Frey M, Rieder H, Korte B, et al. BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 2003; 95:214-21.
79. Neglia JP, FitzSimmons SC, Maisonneuve P, Schöni MH, Schöni-Affolter F, Corey M, Lowenfels AB. The risk of cancer among patients with cystic fibrosis. Cystic Fibrosis and Cancer Study Group. N Engl J Med 1995; 332:494-9.
80. Maisonneuve P, Marshall BC, Lowenfels AB. Risk of pancreatic cancer in patients with cystic fibrosis. Gut 2007; 56:1327-8. (Pubitemid 47300446)
81. Groden J, Thliveris A, Samowitz W, Carlson M, Gelbert L, Albertsen H, et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 1991; 66:589-600.
82. Giardiello FM, Offerhaus GJ, Lee DH, Krush AJ, Tersmette AC, Booker SV. Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis. Gut 1993; 34:1394-6.
83. Eberle MA, Pfützer R, Pogue-Geile KL, Bronner MP, Crispin D, Kimmey MB, et al. A new susceptibility locus for autosomal dominant pancreatic cancer maps to chromosome 4q32-4. Am J Hum Genet 2002; 70:1044-8.
84. Earl J, Yan L, Vitone LJ, Risk J, Kemp SJ, McFaul C, et al. Evaluation of the 4q32-34 locus in European familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2006; 15:1948-55.